Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial

PaperCitations, authors & open-access status

Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 226 citations, 2020 year and hybrid oa status.

226
Citations
2020
Year
hybrid
OA Status

Related on ScholarIQ

Chris Rogers
Author
The Lancet
Journal
Retinal Diseases and Treatments
Topic
Retinal Diseases and Treatments
Topic
Drug-Induced Ocular Toxicity
Topic
Retinopathy of Prematurity Studies
Topic
470M+ articles · free account